En­her­tu wins an­oth­er breast can­cer ap­proval, as As­traZeneca and Dai­ichi Sankyo pre­pare to cor­ner the mar­ket

As­traZeneca and Dai­ichi Sankyo’s En­her­tu fran­chise keeps chug­ging along, as the blos­som­ing an­ti­body-drug con­ju­gate racked up an­oth­er ap­proval ear­ly Thurs­day morn­ing.

En­her­tu is now OK’d to treat ad­vanced HER2-pos­i­tive breast can­cer at the sec­ond-line stage, ex­pand­ing up­on its orig­i­nal 2019 ap­proval in­to an ear­li­er treat­ment set­ting. The drug is now ap­proved in three to­tal in­di­ca­tions as sales num­bers on­ly con­tin­ue to grow, with As­traZeneca re­port­ing $166 mil­lion in the first quar­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER